Additional file 1: of Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Conduct of NCT00720941 and NCT01147822 and timing of key study events. Protocol amendment 4 authorized inclusion of patients from NCT01147822 for safety and efficacy analyses. FPFV = first patient first visit. Data from Motzer RJ et al. [8]. Conduct of trials NCT00720941 and NCT01147822. (PDF 111Â kb)